In this evolving landscape, some medical needs are still unmet, such as the identification of prognostic and predictive biomarkers besides PD-L1 expression; inflammatory signatures in blood and tumour samples, tumour immune microenvironment characterisation, and radiomic features should be integrated with clinico-pathological features of NSCLC patients [45,46]. The gene discussed is CD274; the disease is neoplasm.